HDAX Therapeutics

About HDAX Therapeutics

HDAX Therapeutics is focused on precision targeting for breakthrough treatments, developing next-generation medicines using proprietary technology to unlock novel binding mechanisms for improved targeting and better patient outcomes. Starting with HDAC6, they aim to disrupt treatment inadequacies in neurology, cardiometabolic diseases, and more.

Products & Services

HDAC6 Targeting Technology:A novel 2-site binding mechanism delivering highly potent, selective small molecules for enhanced efficacy, pharmacokinetics, and safety, applicable to a wide range of diseases including neurology and cardiometabolic indications.

Specialties

HDAC6 targeting Small molecule drug design Neurology treatments Cardiometabolic disease treatments 2-site binding mechanism

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 3200000 MR: - FA: US$3.2 million FAN: 3200000	D: 2024-09-05 FD: 2024-09-05	5 investors

Seed Latest

2024-09-05

$3.2M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Patrick Gunning

Co-Founder

N

Nabanita Nawar

CEO & Co-founder

P

Pimyupa Manaswiyoungkul

COO & Co-founder

R

Roman Fleck

Director

N

Neal Muni

Director

B

Brock Reeve

Director

View 6 more team members with Pro

Unlock Full Team Directory

Recent News